Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Motor Activity 2Thrombocythemia, Essential 1Rehabilitation Exercise 1Primary Myelofibrosis 1Polycythemia Vera 1Overweight 1Obesity 1Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Brain Neoplasms 1

Interventions

Paclitaxel 8Carboplatin 7Tirzepatide 3Observation 3Cisplatin 3pembrolizumab 2dostarlimab 2Megestrol Acetate 2Medroxyprogesterone Acetate 2Blood Specimen Collection 2trilaciclib 1toripalimab 1tislelizumab 1sintilimab 1semaglutide 1olaparib 1montelukast 1inavolisib 1enfortumab vedotin 1ceralasertib 1camrelizumab 1apatinib 1anlotinib 1Watchful Waiting 1Vaginal Smears 1Topotecan 1Tablets 1Specimen Handling 1Sensitivity Training Groups 1Resistance Training 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Endometrial Neoplasms × Resistance Training × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡